A Comparative Study of Treatment Toxicities Between FOLFOX 4 and Modified FOLFOX 6 in Iranian Colorectal Cancer Patients
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 1
Abstract
Background: Colorectal cancer is one major health problem and cancer-related cause of death in cancer patients in countries such as Iran where the most cases are diagnosed in advanced stages. Objectives: To evaluate the incidence and severity of toxic effects in colorectal cancer patients who have been treated with two different schedules of combination of oxaliplatin and bolus/infusional 5-fluorouracil with leucovorin (FOLFOX) and to compare them. Methods: Medical records of 458 patients with colorectal cancer treated with FOLFOX 4 and modified FOLFOX 6 regimen between 2005 and 2014 were reviewed. Data from 96 eligible patients were analyzed. Fifty-six patients (58.3%) received FOLFOX 4 and 40 patients (41.7%) received modified FOLFOX 6. Results: The study included 96 patients, 39 of whom were males (40.6%) and 57 of whom were females (59.4%). The median age was 62 years (range: 38 - 87 years). The follow up duration was between 16 - 109 months with a median of 62 months. There was a statistically significant incidence rate of grade 1 toxicity of diarrhea as gastrointestinal (GI) toxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.034), but there was not a statistically significant incidence rate of grade 1 toxicity of stomatitis as GI toxicity between the two regimens (P = 0.27).We observed a highly statistically significant incidence rate of grade 1 toxicity of neutropenia as hematologic toxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P < 0.001), but we did not observe any statistically significant differences of grade 1 of thrombocytopenia as hematologic toxicity between the two regimens (P = 0.063). There was a statistically significant incidence rate of grade 1 neurotoxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.017). Conclusions: We showed that in colorectal cancer patients treated with modified FOLFOX6. Some of hematological and nonhematological complications were more than FOLFOX4 and they can be concerned.
Authors and Affiliations
Keywords
Related Articles
- EP ID EP237281
- DOI -
- Views 69
- Downloads 0
Production of Specific Anti-EGFR Single Chain Antibodies: A Promising Strategy in the Immunotherapy of EGFR Expressing Tumor Tissues
Background: EGFR (Epidermal growth factor receptor) is overexpressed in a number of cancers and plays an important role in several phenomena such as aggressiveness of tumor, decreased survival of the patient, and resista...
Enhancement of Cisplatin Efficacy by Gold Nanoparticles or Microwave Hyperthermia? An In Vitro Study on a Melanoma Cell Line
Purpose: Chemotherapy-resistance of melanoma has led to poor prognosis and decreased survival in the patients. Therefore, the addition of adjuvant therapies to the conventional chemotherapy regimens has been taken into c...
Topical Calcineurin Inhibitors and Malignancy Risk
Context The approval of topical calcineurin inhibitors (TCIs) has been a significant breakthrough for the treatment of atopic dermatitis due to much lower systemic absorption and...
Investigation of Stigma Phenomenon in Cancer: A Grounded Theory Study
Background Adjustment to cancer as a stressful event is affected by bio-psycho-social factors. Objectives This study aimed to investigate stigma phenomenon, the process of formati...
Comparison of Three Clinical Models for Estimating the Risk of Endometrial Cancer in Post-Menopausal Women with Abnormal Vaginal Bleeding
Background: Given the prevalence of abnormal post-menopausal bleeding and the importance of its early examination for ensuring the timely diagnosis of any malignancies, the present study was conducted to investigate uter...